Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy

Hyung Sook Kim; Jae Seob Lee; Hong Kyung Lee; Eun Jae Park; Hye Won Jeon; Yu Jeong Kang; Tae Yong Lee; Kyung Suk Kim; Sang-Cheol Bae; Ji Hyun Park; Sang-Bae Han

doi:10.4110/in.2019.19.e36

Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy

Immune Netw. 2019 Oct 14;19(5):e36. doi: 10.4110/in.2019.19.e36. eCollection 2019 Oct.

Authors

Affiliations

¹ College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea.
² Bioengineering Institute, Corestem Inc., Seoul 04763, Korea.
³ Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea.
⁴ College of Pharmacy, Korea University, Sejong 30019, Korea.

Abstract

Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and serum creatinine levels in ADR-treated mice. MSCs also prevented podocyte damage and renal fibrosis by decreasing the expression of fibronectin, collagen 1α1, and α-smooth muscle actin. From a mechanistic perspective, MSCs inhibited renal inflammation by lowering the expression of CCL4, CCL7, CCL19, IFN-α/β, TGF-β, TNF-α, and chitinase 3-like 1. In summary, our data demonstrate that MSCs improve renal functions by inhibiting renal inflammation in ADR-induced nephropathy.

Keywords: Fibrosis; Inflammation; Mesenchymal stem cells; Podocytes.